About Valeritas
Valeritas is a company based in Bridgewater (United States) founded in 2003 was acquired by Zealand Pharma in February 2020.. Valeritas has raised $181.36 million across 6 funding rounds from investors including Welsh, Carson, Anderson & Stowe, Zealand Pharma and Abingworth. The company has 141 employees as of December 31, 2019. Valeritas has completed 1 acquisition, including Andover. Valeritas offers products and services including Afrezza, V-Go, and Technosphere. Valeritas operates in a competitive market with competitors including scPharmaceuticals, Crossject, CeQur, Vaxxas and Incline Therapeutics, among others.
- Headquarter Bridgewater, United States
- Employees 141 as on 31 Dec, 2019
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mannkind Corporation
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$181.36 M (USD)
in 6 rounds
-
Latest Funding Round
$25.2 M (USD), Post-IPO
May 04, 2016
-
Investors
Welsh, Carson, Anderson & Stowe
& 13 more
-
Employee Count
141
as on Dec 31, 2019
- Investments & Acquisitions
-
Acquired by
Zealand Pharma
(Feb 10, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Valeritas
Valeritas offers a comprehensive portfolio of products and services, including Afrezza, V-Go, and Technosphere. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhaled powder for managing diabetes blood sugar levels.
Patch device for continuous insulin administration.
Platform for delivering drugs via inhalation.
Unlock access to complete
Funding Insights of Valeritas
Valeritas has successfully raised a total of $181.36M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25.2 million completed in May 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $25.2M
-
First Round
First Round
(10 Nov 2008)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2016 | Amount | Post-IPO - Valeritas | Valuation |
investors |
|
| Jul, 2014 | Amount | Series D - Valeritas | Valuation |
investors |
|
| Jun, 2013 | Amount | Debt – Conventional - Valeritas | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Valeritas
Valeritas has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Welsh, Carson, Anderson & Stowe, Zealand Pharma and Abingworth. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CRG is recognized as a premier healthcare investment partner.
|
Founded Year | Domain | Location | |
|
Early-stage investments in US tech and life sciences are targeted.
|
Founded Year | Domain | Location | |
|
Venture capital investments in tech and healthtech sectors through dedicated funds.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Valeritas
Valeritas has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Andover. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Limited information is provided on core activities.
|
1996 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Valeritas
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Valeritas Comparisons
Competitors of Valeritas
Valeritas operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as scPharmaceuticals, Crossject, CeQur, Vaxxas and Incline Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure
|
|
| domain | founded_year | HQ Location |
Needle-free self-injectable drugs
|
|
| domain | founded_year | HQ Location |
Wearable insulin delivery patches are developed for mealtime dosing.
|
|
| domain | founded_year | HQ Location |
Developer of vaccines to treat cancer and infectious diseases
|
|
| domain | founded_year | HQ Location |
Hospital-focused specialty pharmaceuticals are developed for acute pain management.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Valeritas
Frequently Asked Questions about Valeritas
When was Valeritas founded?
Valeritas was founded in 2003 and raised its 1st funding round 5 years after it was founded.
Where is Valeritas located?
Valeritas is headquartered in Bridgewater, United States. It is registered at Bridgewater, New Jersey, United States.
Is Valeritas a funded company?
Valeritas is a funded company, having raised a total of $181.36M across 6 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $100M, raised on Nov 10, 2008.
How many employees does Valeritas have?
As of Dec 31, 2019, the latest employee count at Valeritas is 141.
What does Valeritas do?
Valeritas was founded in 2003 in Bridgewater, United States, within the medical devices sector focused on diabetes management. Wearable insulin patch pumps are produced for skin-based insulin delivery, holding a one-day supply of fast-acting insulin. Continuous preset basal rates are used for release, supplemented by on-demand bolus dosing at mealtimes. Programmability and electricity are not required in the devices, with preset options available for varying daily insulin amounts.
Who are the top competitors of Valeritas?
Valeritas's top competitors include scPharmaceuticals, Crossject and Vaxxas.
What products or services does Valeritas offer?
Valeritas offers Afrezza, V-Go, and Technosphere.
How many acquisitions has Valeritas made?
Valeritas has made 1 acquisition, including Andover.
Who are Valeritas's investors?
Valeritas has 14 investors. Key investors include Welsh, Carson, Anderson & Stowe, Zealand Pharma, Abingworth, CRG, and Montrose Capital Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.